Keyphrases
Circulating Tumor DNA (ctDNA)
100%
Prostate Cancer
64%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
56%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
37%
Enzalutamide
37%
Abiraterone
37%
Androgen Receptor
30%
Tumor
27%
Fibroblast Growth Factor Receptor 3 (FGFR3)
23%
Long Non-coding RNA (LncRNA)
22%
Castration-resistant Prostate Cancer
21%
Genotype
19%
Androgen Signaling
18%
Diffuse Glioma
17%
Overall Survival
16%
Prostate Tumor
16%
Androgen Receptor Antagonist
16%
Metastasis
15%
Advanced Prostate Cancer
15%
Prostate Cancer Patients
14%
Clinical Outcomes
14%
Targeted Sequencing
14%
Clinical Genomics
14%
Liquid Biopsy
14%
Fibroblast Growth Factor Receptor 1 (FGFR1)
13%
Pathway Inhibitors
13%
Tumor Tissue
13%
Lung
13%
Genomic Features
13%
IDH-mutant Astrocytoma
13%
Evolutionary History
12%
Multi-region Sampling
12%
Online Treatment
12%
Aggression
12%
Clinical Association
12%
Whole Genome
12%
DNA Sequencing
12%
Transcriptome Sequencing
12%
Phase II Trial
12%
Treatment-resistant
12%
Poor Prognosis
12%
Cell-free DNA (cfDNA)
12%
DNA Repair Genes
11%
Molecular Taxonomy
11%
Somatic Features
11%
Association Analysis
11%
5-hydroxymethylcytosine (5hmC)
11%
Pilocytic Astrocytoma
11%
Ependymoma
11%
Resistant Prostate Cancer
11%
Biochemistry, Genetics and Molecular Biology
Circulating Tumor DNA
92%
Androgen Receptor
61%
Genomics
60%
Blood Plasma
32%
DNA Repair
30%
Genotyping
27%
Enzalutamide
24%
Long Noncoding RNA
22%
RNA Sequencing
15%
Overall Survival
15%
Allele
14%
Immunoglobulin Producing Cell
14%
Oncogene
14%
Clinical Genomics
13%
SPOP
13%
Evolution
12%
Phase II Trials
12%
Epidermal Growth Factor Receptor
11%
Gene Drive
11%
FOXA1
11%
Protein Tyrosine Phosphatase Receptor Delta
11%
CNTNAP2
11%
Transcription Factor 3
11%
Insulin-Like Growth Factor-Binding Protein
11%
STAT Protein
11%
AKT1
11%
SKIL
11%
IDH1
11%
HOXB13
11%
Prospective Study
11%
5-Hydroxymethylcytosine
11%
BRCA2
11%
Germ Cell
11%
Germline
11%
HSD3B1
11%
Transcription Factors
11%
Chromatin Immunoprecipitation
11%
Single Nucleotide Polymorphism
10%
Cancer Cell
9%
Whole Genome Sequencing
9%
Enhancer Region
8%
Promoter Region
8%
Binding Site
8%
Chromosomal Rearrangement
8%
Prostate-Specific Antigen
7%
Gene Fusion
7%
Tumor Progression
6%
Cell Proliferation
5%
MAPK Signaling
5%
ETV1
5%
Medicine and Dentistry
Prostate Cancer
96%
Circulating Tumor DNA
65%
Neoplasm
59%
Castration Resistant Prostate Cancer
47%
Malignant Neoplasm
24%
Enzalutamide
22%
Abiraterone
22%
Somatics
22%
Androgen Receptor
20%
Ganglioglioma
19%
Cell-Free DNA
19%
Metastatic Carcinoma
17%
Biological Marker
16%
Oligoastrocytoma
14%
Fibroblast Growth Factor Receptor 3
13%
Lung
13%
Phase II Trials
12%
Liquid Biopsy
12%
RNA Sequencing
12%
Epidermal Growth Factor Receptor
12%
Overall Survival
11%
5 Hydroxymethylcytosine
11%
Cabazitaxel
11%
Non Muscle Invasive Bladder Cancer
11%
STAT Protein
11%
Transcription Factor 3
11%
Somatomedin Binding Protein 2
11%
Immunotherapy
11%
Metastatic Bladder Cancer
11%
Krukenberg Tumor
11%
Oligodendroglioma
11%
Long Untranslated RNA
11%
Minimal Residual Disease
11%
Evolution
11%
Diseases
10%
DNA Repair
9%
Cancer
7%
The Cancer Genome Atlas
6%
Gene Mutation
6%
Biopsy Technique
6%
Transitional Cell Carcinoma
6%
Progression Free Survival
5%
Androgen
5%
